OR WAIT null SECS
Leiden site will be the company's fifth such facility, and first in Europe
Bristol Myers Squibb has chosen Leiden, Netherlands, as home to its first European cell therapy manufacturing site. Construction is projected to commence later this year.
The pharma company said it decided to make this investment to further develop its global manufacturing capacity and provide treatments to patients faster. Leiden will be BMS' fifth cell therapy manufacturing site, in addition to major contract manufacturing partnerships globally.
“A key element of BMS’ commitment to cell therapy is our continuous investment in advanced manufacturing capabilities, from the expansion of our global network and capacity to treat patients to reduced turnaround time and optimized costs,” said Ann Lee, PhD, senior vice president, cell therapy development and operations, BMS. “We continue to grow our presence in Europe and the Netherlands, which offers an innovative life sciences hub and world-class industry talent, and we look forward to hiring several hundred talented people over the coming years to join our global team and participate in our cell therapy journey.”